|
|
News Breaks | | | | October 31, 2012 | | 07:09 EDT |  | SGEN | Seattle Genetics' Adcetris receives European Commission marketing authorization
Seattle Genetics' collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical, announced that the European Commission has granted conditional marketing authorization for Adcetris (brentuximab vedotin). Adcetris was approved for two indications: (1) the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. As a result, under the collaboration Seattle Genetics will receive two milestone payments from Millennium, one for each indication, totaling $25M. ADCETRIS is an antibody-drug conjugate directed to CD30. | |
|
News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks. |
|
|
| May 14, 2013 | | 09:04 EDT | | SGEN | Seattle Genetics announces ADCETRIS supplemental filing accepted by FDA
 Subscribe for More Information | | | May 7, 2013 | | 16:22 EDT |  | SGEN | Seattle Genetics reports Q1 EPS (14c), consensus (20c)
Subscribe for More Information | |
|
|
|
|
|
|
